2005•The Journal of UrologyRequires access

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer

Patrick C. Walsh

Open publisher page 324 citations

Abstract

No AccessJournal of UrologyUrological Survey: Urological Oncology: Prostate Cancer1 Feb 2005Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer Patrick C. WalshM.D. Patrick C. WalshPatrick C. Walsh More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)60500-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer." The Journal of Urology, 173(2), p. 456 © 2005FiguresReferencesRelatedDetails Volume 173Issue 2February 2005Page: 456 Advertisement Copyright & Permissions© 2005MetricsAuthor Information Patrick C. Walsh More articles by this author Expand All Advertisement PDF downloadLoading ...

About this research paper

What this paper is about

No AccessJournal of UrologyUrological Survey: Urological Oncology: Prostate Cancer1 Feb 2005Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer Patrick C. WalshM.D. Patrick C. WalshPatrick C. Walsh More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)60500-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer." The Journal of Urology, 173(2), p. 456 © 2005FiguresReferencesRelatedDetails Volume 173Issue 2February 2005Page: 456 Advertisement Copyright & Permissions© 2005MetricsAuthor Information Patrick C. Walsh More articles by this author Expand All Advertisement PDF downloadLoading ...

Why it matters

OpenAlex reports 324 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

No AccessJournal of UrologyUrological Survey: Urological Oncology: Prostate Cancer1 Feb 2005Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer Patrick C. WalshM.D. Patrick C. WalshPatrick C. Walsh More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)60500-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer." The Journal of Urology, 173(2), p. 456 © 2005FiguresReferencesRelatedDetails Volume 173Issue 2February 2005Page: 456 Advertisement Copyright & Permissions© 2005MetricsAuthor Information Patrick C. Walsh More articles by this author Expand All Advertisement PDF downloadLoading ...

Key concepts: Prednisone, Medicine, Mitoxantrone, Docetaxel, Prostate cancer, Urology, Prostate, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer — Research Paper | ScholarLens